
Revolutionizing the Science of Antimicrobial Protection



The first Central Venous Catheter with an integrated antimicrobial material

Edwards Vantex Catheter with Oligon Agent



A family of venous access technologies

Edwards offers other members of the access family, including introducers and central venous catheters, as well as a full line of Edwards Swan-Ganz Catheters, disposable pressure transducers and a blood management protection system.

For additional information, call your Edwards representative at (800) 424-3278, or visit www.edwards.com for details.

the activity of the antimicrobial agent is localized at the catheter surfaces and is not intended for treatment of systemic infections. In vitro testing demonstrated that the Oligon agent provided broad spectrum effectiveness (≥ 3 log reduction from initial concentration within 48 hours) against the organisms tested: Staphylococcus aureus, Staphylococcus epidermidis, Klebsiella pneumoniae, Enterococcus faecalis, Candida albicans, Escherichia coli, Serratia marcescens, Acinetobacter calcoaceticus, Corynebacterium diptheriae, Enterobacter aerogenes, GMRSa, Pseudomonas aeruginosa, Candida albatata and VRE (Enterococcus faecium).

Edwards Lifesciences, Edwards, and the stylized E logo are trademarks of Edwards Lifesciences Corporation. Swan-Ganz and Vantex are trademarks of Edwards Lifesciences Corporation and are registered in the U.S. Patent and Trademark Office. Interlink is a trademark of Baxter International Inc., registered in the U.S. Patent and Trademark Office. Oligon is a trademark of Implemed, Inc.

Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. See instructions for use for full prescribing information.

Edwards Lifesciences devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

© 2004 Edwards Lifesciences LLC. All rights reserved. AR00486-A4

References

Data on file. Edwards Lifesciences LLC.

 Ranucci M, et al. Impact of oligon central venous catheters on catheter colonization and catheter-related bloodstream infection. Crit Care Med 2003;31(1):52-59.

Garcia R, et al. Three years experience in implementing HICPAC recommendations for the reduction of central venous catheter-related bloodstream infections. Poster Presentation at National APIC Meeting, June 2003.

 Berger TJ, et al. Electrically generated silver ions: quantitative effects on bacterial and mammalian cells. Antimicrobial Agents and Chemotherapy 1976;9(2):357-358.

